10 January 2023
Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Full Year Trading Update – In Line with Expectations
Winsford, UK : Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, today announces its unaudited trading update for the year ended 31 December 2022 (the “Period”).
The Group is pleased to report that trading for the Period was strong as both Business Units continued to perform well. Group revenues and profits for the Period are expected to be in line with market expectations.
AMS also made good progress during 2022 in its regulatory and clinical programmes including the US approval of LiquiBand® XL in May and the submission of a PMA for LiquiBandFix8® in October. The initial European SEAL-G® clinical trial also continues to progress well with over two-thirds of patients now recruited and remains on track for completion in the first half of this year.
The Group expects to announce its preliminary results on Wednesday 15 March 2023.
Chris Meredith, Chief Executive Officer of AMS, commented : “I am very pleased to report that AMS continued to perform strongly in 2022 despite the macro-economic challenges. This is a testament to the resilience of our business model and the strength of our staff who have worked so hard to achieve this result. The progress we have made with our regulatory programmes is particularly significant and represents a major step forward in our plan to gain further traction in the US market. The underlying momentum throughout the Group, which has been further strengthened with promising new products, gives us confidence of meeting market expectations for 2023 and sustaining our growth profile in the long term.”
– End –